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FDA Restrictions on Mifepristone: Time for a Change?
Abstract
Mifepristone, a drug used to manage early miscarriage or end an early pregnancy, carries unique
restrictions imposed by the U.S. Food and Drug Administration (FDA). Patients are required to pick up the
drug in person from a doctor or a clinic, even though they can take the drug at home. In July, a federal
court ruled that the FDA must suspend these restrictions during the COVID-19 pandemic, for patients
seeking an early abortion, although the ruling did not apply to women with an early pregnancy loss. But
the challenges to FDA restrictions on mifepristone predate the pandemic. This Issue Brief provides the
context for this ongoing controversy, and reviews recent evidence on the clinical and cost effectiveness of
mifepristone for the medical management of first trimester miscarriage.
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Issue BRIEF
FDA RESTRICTIONS ON MIFEPRISTONE:
TIME FOR A CHANGE?
Recent studies confirm clinical and cost effectiveness for
medical management of early miscarriage
Janet Weiner, PhD, MPH and Courtney A. Schreiber, MD, MPH

Mifepristone, a drug used to manage early miscarriage or end an early pregnancy, carries unique restrictions
imposed by the U.S. Food and Drug Administration (FDA). Patients are required to pick up the drug in person
from a doctor or a clinic, even though they can take the drug at home. In July, a federal court ruled that the
FDA must suspend these restrictions during the COVID-19 pandemic, for patients seeking an early abortion,
although the ruling did not apply to women with an early pregnancy loss. But the challenges to FDA restrictions
on mifepristone predate the pandemic. This Issue Brief provides the context for this ongoing controversy, and
reviews recent evidence on the clinical and cost effectiveness of mifepristone for the medical management of
first trimester miscarriage.

INTRODUCTION
The FDA approved mifepristone (also known as RU486) in 2000
with safety restrictions that involve a Risk Evaluation and Mitigation
Strategy (REMS). Under REMS, mifepristone must be dispensed
through registered clinicians only, and patients must sign an FDAapproved agreement before receiving the medication. By most
accounts, these restrictions stem from the use of mifepristone, in
combination with another medication, misoprostol, for medicallyinduced early abortion. As a result, mifepristone is not available
through retail or mail-order pharmacies, and most physicians do not
stock the drug.

In the 20 years since then, medical professional organizations and
advocacy groups have challenged these restrictions in court, citing
evidence of drug’s safety and efficacy. In July 2020, a federal district
court held that the FDA could not enforce these restrictions on
women seeking a medical abortion during a pandemic, because of the
risk posed by requiring in-person visits to pick up the medication. The
ruling raises longer-term questions about whether the FDA should
reconsider the REMS restrictions entirely, especially in light of recent
evidence on the clinical and cost effectiveness of mifepristone in the
medical management of early miscarriage.
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economic evaluation alongside the clinical trial to estimate the costeffectiveness of adding mifepristone to the medical management of
miscarriage. In a study published in earlier this year in JAMA Network
Open, they found that mifepristone pretreatment represents good
value from both the perspective of the health sector and society.2

Each year, more than one million women in the United States
miscarry in the first trimester. Often, ultrasound reveals a nonviable
pregnancy, and women face the difficult and painful choice of waiting
for a miscarriage to progress, or surgical or medical interventions
to help complete the miscarriage process. Many women prefer
medical management (medications that they can take at home to
induce uterine contractions) rather than surgery (uterine aspiration).
The most commonly used medical therapy is misoprostol (selfadministered), which fails about 30% of the time, leading to prolonged
treatment or eventual surgical management. Another option is to give
women mifepristone first (orally) followed by misoprostol, 24 hours
later. However, the FDA restrictions on mifepristone have limited
access to the drug and, until recently, the efficacy of pretreating with
mifepristone was unclear in these circumstances.

They analyzed direct health care costs in the 30 days after enrollment
in the trial, as well as more indirect societal costs such as patients’ time
and lost wages. They found that average health care costs were the
same in the two groups: in 2018 dollars, $697 for women receiving
mifepristone and misoprostol versus $691 for women receiving
misoprostol alone. From the societal perspective, average costs per
patient were $3,846 for mifepristone and misoprostol and $4,846 for
misoprostol alone — a $1,000 difference.

REMS AND THE REGULATION
OF MIFEPRISTONE
Currently, the FDA has 59 REMS programs in place, 86% of which
include “elements to assure safe use” such as clinician registration
or special training. The programs are usually applied to drugs with
serious complications or contraindications, such as antipsychotics,
opioids, testosterone, and several drugs used to treat cancer, acne,
and multiple sclerosis.

RANDOMIZED TRIAL SHOWS MIFEPRISTONE
PRETREATMENT IS 25% MORE EFFECTIVE
THAN MISOPROSTOL ALONE
Courtney Schreiber and colleagues conducted a randomized trial
of mifepristone pretreatment in 300 women with early pregnancy
loss, and assessed its efficacy and safety compared to misoprostol
only. The landmark study, published in the New England Journal of
Medicine, found that pretreatment with mifepristone was more 25%
more effective than misoprostol alone in successful management of
early pregnancy loss.1 The combination of drugs led to completion
of the miscarriage after one course of treatment in 83.8% of
women, compared to 67.1% of women receiving misoprostol alone.
Fewer women in the pretreatment group needed eventual surgical
intervention (8.8% vs. 23.5%). In terms of safety, the study found
no significant difference between the groups in adverse events
(infections or blood transfusions).

In response to 15 years of safety information, in 2016 the FDA
revised its initial REMS requirements for mifepristone. The changes
included expansion of the gestational limit for treatment from 49 to
70 days, omission of the recommendation for in-person follow-up, and
removal of a requirement that the prescriber be a physician. However,
the requirement that the drug be dispensed by a certified provider
remained intact.
In 2017, the American Civil Liberties Union (ACLU) filed a lawsuit, on
behalf of a group of providers, challenging the REMS requirements
for mifepristone. They cited low rates of complications associated with

The study provided compelling evidence that pretreatment with
mifepristone is safe and effective for women with early pregnancy
loss. After the study was released in 2018, the American College of
Obstetrics and Gynecology called for the removal of “outdated”
REMS requirements for mifepristone, saying that the restrictions
substantially limit access to a safe, effective medication.

In 2018, the American College of
Obstetrics and Gynecology called
for the removal of “outdated” REMS
requirements for mifepristone, saying

MIFEPRISTONE PRETREATMENT
IS COST EFFECTIVE

that the restrictions substantially limit

Another consideration in the use of mifepristone pretreatment is
whether it is cost effective, at roughly $90 a pill (misoprostol alone
can cost less than one dollar). Schreiber and colleagues conducted an

access to a safe, effective medication.
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The temporary easing of the in-person requirements
allows mifepristone to be mailed from health facilities to
the patient where state law permits. The injunction will last
for the duration of the litigation, or until the administration
ends the federal public health emergency declaration.

medical abortions and pointed to other drugs with more serious risks that did not carry REMS
restrictions. The suit maintains that the REMS restrictions needlessly complicate access to the
drug, particularly in rural or medically underserved areas. That case is still pending.
In 2019, a former FDA Commissioner published a perspective in the New England Journal of
Medicine arguing the distribution restrictions imposed by the FDA were no longer appropriate
given nearly two decades of use and evidence that mifepristone is extremely safe and effective.
And in response to the COVID-19 pandemic, the ACLU filed another lawsuit challenging the
REMS requirement that mifepristone be dispensed in person. The court issued a nationwide
preliminary injunction blocking part of the FDA’s REMS restrictions on mifepristone when it is
used for medication abortion, yet failed to suspend the restrictions when the medication is used
for managing an early miscarriage. The temporary easing of the in-person requirements allows
mifepristone to be mailed from health facilities to the patient where state law permits. The
injunction will last for the duration of the litigation, or until the administration ends the federal
public health emergency declaration.
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The latest evidence of mifepristone’s clinical and cost effectiveness adds an important
perspective to the controversy surrounding its regulation and availability. REMS regulations
were promulgated when existing safety data were scarce amid debates about medical abortion.
But for women with early pregnancy loss, experts believe that restrictive regulations reduce
access to now-recommended medical regimens to manage the process of miscarriage. The
evidence on the clinical and cost effectiveness of mifepristone pretreatment is clear, and
warrants a new look by FDA regulators. And in the midst of a pandemic, requiring in-person
dispensing is a risk no woman with an early pregnancy loss should have to face.
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